The commonly reported side effect, nausea,3, 6, 8 appears less likely to influence the obtained data as the Ex4‐NAc shell dose and the Ex4‐IP dose do not alter kaolin intake,20, 22 and the treatment protocols of the various GLP‐1R agonists have been adjusted to reduce the risk of malaise. The gene discussed is GLP1R; the disease is malaise.